HEALTHSTAT NEWS
STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ case
The Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe on Amarin's patents, supporting the use of 'skinny labeling' by generic drugmakers. This decision overturns a lower court ruling and reduces legal risks for generic companies marketing drugs for specific uses to avoid patent infringement lawsuits.
Mentioned
Related Signal
Adjacent reporting
- Supreme Court rules on fight between drugmakers in "skinny label" patent case
- STAT+: Colombia wins a key court ruling over a compulsory license issued for an HIV medicine
- STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
- Opinion: Mifepristone court ruling makes drug development riskier for everyone
- Why Canada has generic Ozempic, and the US doesn't
- How a Supreme Court fight over fish oil could raise your prescription drug costs